Omnix Medical advances first-in-class antimicrobial OMN6 into Phase II trials
Targeting deadly drug-resistant acinetobacter infections
Targeting deadly drug-resistant acinetobacter infections
First-in-class treatment of life-threatening, drug-resistant Acinetobacter baumannii infections advancing toward Phase II clinical proof-of-concept
The approval marks a major milestone in the global fight against antimicrobial resistance
The U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergies
Subscribe To Our Newsletter & Stay Updated